Oxycodone/naloxone

Oxycodone/naloxone
Combination of
Oxycodone Opioid analgesic
Naloxone Opioid receptor antagonist
Clinical data
AHFS/Drugs.com International Drug Names
UK Drug Information
  • C
Oral
Identifiers
 Yes
N02AA55
 Yes (what is this?)  (verify)

The combination oxycodone is an opioid analgesic available as managed-release tablets under the trade names Targin (produced by Mundipharma), Targiniq and Targinact. Oxycodone is responsible for the pain-relieving effects, while naloxone reduces opioid-induced euphoria, as well as constipation. Constipation was significantly relieved in a 2008 study.[1] The drug was released in 2006 in Germany and is available in some other European countries since 2009.[2]

Adverse effects

Further information: Oxycodone § Adverse effects

See also

References

  1. ↑ Simpson K et al. (December 2008). "Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain". Curr Med Res Opin 24 (12): 3503–3512. doi:10.1185/03007990802584454. PMID 19032132. Retrieved 2009-04-09.
  2. ↑ Mundipharma (2009-01-26). "Targin (oral oxycodone/naloxone prolonged-release tablet) now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation". Retrieved 2009-04-09.